Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Atara Biotherapeutics (ATRA) Revenue (2022 - 2025)

Atara Biotherapeutics' Revenue history spans 4 years, with the latest figure at $1.6 million for Q4 2025.

  • For Q4 2025, Revenue fell 95.13% year-over-year to $1.6 million; the TTM value through Dec 2025 reached $120.8 million, down 6.33%, while the annual FY2025 figure was $120.8 million, 6.33% down from the prior year.
  • Revenue reached $1.6 million in Q4 2025 per ATRA's latest filing, down from $3.5 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $98.1 million in Q1 2025 to a low of $221000.0 in Q4 2022.
  • Average Revenue over 4 years is $20.1 million, with a median of $5.9 million recorded in 2022.
  • Peak YoY movement for Revenue: tumbled 98.46% in 2023, then soared 3511.6% in 2024.
  • A 4-year view of Revenue shows it stood at $221000.0 in 2022, then soared by 1795.48% to $4.2 million in 2023, then soared by 681.88% to $32.8 million in 2024, then crashed by 95.13% to $1.6 million in 2025.
  • Per Business Quant, the three most recent readings for ATRA's Revenue are $1.6 million (Q4 2025), $3.5 million (Q3 2025), and $17.6 million (Q2 2025).